However, the GPX4 inhibitor, which acts as an antioxidant, displays greater sensitivity towards CD8+T cells and CD4+T cells, leading to a preferential induction of ferroptosis in killer T cells rather than tumor cells. The gene discussed is CD8A; the disease is neoplasm.